SPPI - スペクトラム・ファ―マス―ティカルズ （Spectrum Pharmaceuticals Inc.）

Spectrum Pharma (NASDAQ: SPPI ) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Spectrum Pharma beat estimated earnings by 66.67%, reporting an … Full story available on Benzinga.com

Spectrum Pharmaceuticals (SPPI) rose ~10% Tuesday pre-market after the biopharmaceutical company said its Q1 net sales increased by 54% on a quarterly basis.

Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum Pharmaceuticals in All St…

BOSTON (AP) — BOSTON (AP) — Spectrum Pharmaceuticals Inc. (SPPI) on Tuesday reported a loss of $5 million in its…

BOSTON--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update. First Quarter 2023 and Recent Business Update Net sales for Q1 2023 totaled $15.6 million, an increase of 54% compared to Q4 2022. 172 targeted accounts purchased ROLVEDON™ (eflapegrastim-xnst) Injection during the

The share price of Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) rose to $0.81 per share on Friday from $0.81. While Spectrum Pharmaceuticals Inc. has overperformed by 0.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SPPI rose by 3.15%, with highs and lows ranging from $1.57 to $0.31, […]

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)’s traded shares stood at 1.95 million during the last session, with the company’s beta value hitting 2.13. At the close of trading, the stock’s price was $0.81, to imply an increase of 0.52% or $0.0 in intraday trading. The SPPI share’s 52-week high remains $1.57, putting it -93.83% down since that … Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) Has Succeeded In Generating Interest In 2023, The Stock Is Up 119.81% Year-To-Date Read More »

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Spectrum common stock between December 6, 2021 through September 22, 2022, inclusive (the “Class Period”). Such investors are encouraged to join this case by vi

LOS ANGELES--(BUSINESS WIRE)---- $SPPI #SPPI--The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. New molecular entity approvals drew a blank in August. NMEs are those active moieties that have not been previously approved by the FDA. This should be a cause of concern, as NME approvals are considered a measure of innovation in drug research. The fortunate ones that could take their drugs past the finish line included bluebird bio, Inc. (NASDAQ: BLUE ), Johnson & Johnson (NYSE: JNJ ), and Axsome Therapeutics, Inc. (NASDAQ: AXSM ). ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD ) faced rejection for expanding the label of its Nuplazid to be able to treat Alzheimer’s disease psychosis. CorMedix, Inc.’s (NASDAQ: CRMD ) defencath application was shot down by the FDA for a second time. The review period for Amicus Therapeutics, Inc.’s (NASDAQ: FOLD ) Pompe disease treatment was extended. The Prescription Drug User Fee Act, or PDUFA, date is the period by which the FDA is required to rule on an application submitted by a sponsor company.

SPPI focuses on developing and commercializing novel and targeted drug products with a primary focus in oncology. Read more to see the full investment analysis.

SPPI earnings call for the period ending June 30, 2022.

Spectrum Pharma (SPPI) is trading ~9% higher after the company said the U.S. Food and Drug Administration completes re-inspection of drug substance manufacturing facility for…